AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...

AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck ...

Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings The PFS improvement was seen across all pre-specified patient subgroups ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer ... Enhertu’s label carries a black box warning ...

Sir Pascal Soriot, AstraZeneca’s chief executive ... for terminal breast cancer patients. However, Nice ruled that Enhertu did not offer value for money. The drug is currently not available ...

AstraZeneca ... drug cocktail when it was combined with another medicine, Pertuzumab. The trial was testing Enhertu’s effectiveness against HER2-positive metastatic breast cancer.

Less than three weeks after AstraZeneca ... Daiichi’s R&D chief, said in a release, adding that the results “could offer patients with HER2-positive breast cancer a promising new treatment ...

A new commercial for AstraZeneca’s Truqap ... breast cancer who have experienced recurrence or progression on other treatments. The approval was based on study data showing that the drug combo ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate ... stage breast cancer. As for the study’s secondary ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in patients with HER2-positive ...

AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast cancer.